Asset Details
Do you wish to reserve the book?
Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese Volunteers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese Volunteers
Do you wish to request the book?
Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese Volunteers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese Volunteers
2016
Overview
Background
The pharmacokinetics of milnacipran have been studied in Caucasian subjects but not in Chinese subjects.
Methods
This single-center, open-label study evaluated the pharmacokinetics and safety of oral milnacipran administered as a randomized, three-way crossover, single-dose (25, 50 and 100 mg) and in multiple doses for 8 days (up to 100 mg/day administered as 50 mg twice daily) in Han Chinese healthy volunteers. Both the single- and multiple-dose studies included 12 different adults (six males and six females), respectively. Pharmacokinetic parameters for milnacipran were determined using WinNonlin version 6.3. The safety evaluation included adverse events (AEs) assessed by monitoring, physical examinations, vital signs, and clinical laboratory tests.
Results
Plasma concentrations of milnacipran reached a time to maximum concentration (
t
max
) of 1.2–4.3 h after each single dose, and then declined, with a mean half-life (
t
½
) of 7.0–7.3 h over the dose range of 25–100 mg; the area under the curve (AUC) and maximum concentration (
C
max
) values increased in a dose-proportional manner. After multiple doses, steady state was reached by day 4 and the accumulation was low, with an accumulation index <1.65. No significant sex differences were observed in milnacipran pharmacokinetic parameters and, additionally, no severe AEs were observed in the single- or multiple-dose studies. The most common reported AEs were nausea, vomiting, dizziness and water brash, which appears to be dose-related.
Conclusion
Milnacipran was safe and well-tolerated in healthy volunteers and displayed linear increase in the
C
max
and AUC values at doses ranging from 25 to 100 mg once daily.
Publisher
Springer International Publishing,Springer Nature B.V
